|Bid||0.00 x 36200|
|Ask||0.00 x 2200|
|Day's Range||52.46 - 52.50|
|52 Week Range||15.31 - 52.53|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 24, 2021 - Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.50|
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Moody's Investors Service ("Moody's") assigned a Aaa rating to the new senior unsecured notes offering of Johnson & Johnson ("J&J"). There are no changes to J&J's existing ratings including the Aaa senior unsecured long-term rating and the Prime-1 short term rating. J&J's Aaa rating reflects the company's large scale and market presence, its strong product and geographic diversity, and its high margins.
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the successful completion of its sale to Johnson & Johnson for $52.50 per share, totaling approximately $6.5 billion. The all-cash tender offer by Vigor Sub, Inc. (“Vigor”), a wholly owned subsidiary of Johnson & Johnson, for all outstanding shares of Momenta common stock for $52.50 per share expired at 12:00 a.m. (midnight), New York City time, at the end of the day on September 30, 2020.